Clinical trial • Phase I • Oncology
BMS-986500 for Advanced or metastatic solid tumors | Gastroesophageal cancer | High-grade serous ovarian cancer | Endometrial cancer | Advanced or metastatic breast cancer | Platinum-resistant ovarian cancer
Phase I trial of BMS-986500 for Advanced or metastatic solid tumors | Gastroesophageal cancer | High-grade serous ovarian cancer | Endometrial cancer | Ad…
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced or metastatic solid tumors | Gastroesophageal cancer | High-grade serous ovarian cancer | Endometrial cancer | Advanced or metastatic breast cancer | Platinum-resistant ovarian cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 09-02-2026
- First CTIS Authorization Date
- 26-02-2026
Trial design
None/Not specified-controlled Phase I trial across 2 sites in Denmark.
- Comparator
- None/Not specified
- Target Sample Size
- 66
Recruitment
- Planned Sample Size
- 66
- Recruitment Window Months
- 37
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 66
Denmark
- Earliest CTIS Part Ii Submission Date
- 11-02-2026
- Latest Decision Or Authorization Date
- 26-02-2026
- Processing Time Days
- 15
- Number Of Sites
- 2
- Number Of Participants
- 15
Sites
- Site Name
- Odense University Hospital
- Department Name
- Phase 1 Unit, Dept. of Oncology, Odense University Hospital
- Contact Person Name
- Annette Raskov Kodahl
- Contact Person Email
- ouh.ode.r.kfe@rsyd.dk
- Site Name
- Rigshospitalet
- Department Name
- Department of Oncology, Rigshospitalet, Copenhagen
- Contact Person Name
- Martin Højgaard
- Contact Person Email
- thephaseunit.rigshospitalet@regionh.dk
Sponsor
Primary sponsor
- Full Name
- Bristol-Myers Squibb Services Unlimited Company
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Ireland
Investigational products
- Investigational Product Name
- BMS-986500
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)